Market Overview

Stifel: Aurora's 'Bad' Q4 Extends Beyond Headline Numbers

Share:
Stifel: Aurora's 'Bad' Q4 Extends Beyond Headline Numbers

Cannabis company Aurora Cannabis Inc (NYSE: ACB) (TSE: ACB) reported fiscal fourth-quarter results last week that looked "bad" on the surface, but look even worse when digging beyond the headline numbers, according to Stifel.

The Analyst

W. Andrew Carter downgraded Aurora's Toronto-listed stock rating from Hold to Sell with a price target lowered from CA$7 ($5.29) to CA$5 ($3.78). 

Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.

The Thesis

Aurora's shortfall in the quarter is evident due to a reported $20.1 million of bulk wholesale trim sales that are unlikely to repeat at the same level, Carter said in a Sunday downgrade note. (See his track record here.)

The headline net cannabis revenue of CA$94.7 million suggests a net cannabis revenue base closer to CA$75 million versus Stifel's estimate of CA$92.5 million.

The "lower quality" performance marks a reversal from the company's update in August, when it alluded to a strong in-market performance and a leadership position in Canada, the analyst said. 

Instead, the company recorded CA$44.9 million in adult use sales in Canada, which implies that it lags Canopy Growth Corp (NYSE: CGC), which reported CA$49 million in adult use sales, including a CA$6.5-million charge for potential returns, he said. 

Aurora's report suggests it is far removed from achieving profitability, and any sequential improvement in the reported quarter was "underwhelming" when considering unique events, like a CA$14.9-million benefit from accounting changes, Carter said. 

Looking forward, the analyst said he expects a "more muted" adult use market in the first half of 2020 and sees a likelihood of Aurora's sales hitting a plateau in the near-term.

Sales are likely to accelerate in the back half of the year from "Cannabis 2.0," but the Stifel is moving its full-year revenue target lower from CA$600 million to CA$485 million.

The EBITDA loss for fiscal 2020 was also revised from CA$32 million to a loss of CA$89 million.

The company is likely need to oversee a "significant" capital market raise before the end of the first quarter of 2020 and will ultimately find itself in a difficult position to aggressively invest in the U.S. market, according to Stifel. 

Price Action

Aurora's U.S.-listed shares were down 6.89% at $5.54 at the time of publication Monday. 

Related Links:

The Week In Cannabis: Big Pharma Makes Moves, Diddy & Wahlberg Go After CBD, Medicine Man Continues M&A Spree

Aurora Investors Aren't Feeling The Buzz After Q4 Print: 2 Analyst Takes

 

Latest Ratings for ACB

DateFirmActionFromTo
Oct 2019MaintainsNeutral
Sep 2019Initiates Coverage OnNeutral
Sep 2019Initiates Coverage OnSell

View More Analyst Ratings for ACB
View the Latest Analyst Ratings

Posted-In: Stifel W. Andrew CarterAnalyst Color Cannabis Downgrades Price Target Markets Analyst Ratings Best of Benzinga

 

Related Articles (CGC + ACB)

View Comments and Join the Discussion!

Cannabis Movers

Sign up for our secret cannabis newsletter!
Never miss out on the breaking news in the Cannabis Industry!

Georgia Ports Authority Celebrates "Incredible" Achievements

Report: AMD Ryzen Processors To Supplant Intel In Microsoft's New Surface Laptop 3